Health
FDA Approves Landmark Pancreatic Cancer Drug Rasonque
FDA approves Rasonque (daraxonrasib), a first-in-class targeted therapy that nearly doubled survival in metastatic pancreatic cancer patients.
—6 min read
Tag
1 article
FDA approves Rasonque (daraxonrasib), a first-in-class targeted therapy that nearly doubled survival in metastatic pancreatic cancer patients.